(Q41449159)

30 September 2017

1 reference

title

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy (English)

1 reference

30 September 2017

Reuter VE

1

1 reference

PubMed ID

9123731

30 September 2017

language of work or name

English

0 references

publication date

1 March 1997

1 reference

30 September 2017

1 reference

30 September 2017

49

1 reference

30 September 2017

16-22

1 reference

30 September 2017

3A Suppl

1 reference

Correlation of pathologic findings with progression after radical retropubic prostatectomy

30 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Inhibition of Basal and Adrenocorticotropin-Stimulated Plasma Levels of Adrenal Androgens after Treatment with an Antiandrogen in Castrated Patients with Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4'-nitro-3'trifluoromethylisobutyranilide).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Pathologic changes associated with androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Clinical and Pathobiological Effects of Neoadjuvant Total Androgen Ablation Therapy on Clinically Localized Prostatic Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900164-7

7 January 2021

10.1016/S0090-4295(97)00164-7

Identifiers

DOI

1 reference

30 September 2017

1 reference

PubMed ID

9123731